[go: up one dir, main page]

DE60016209D1 - Hemisynthetisches verfahren und dessen zwischenprudukte - Google Patents

Hemisynthetisches verfahren und dessen zwischenprudukte

Info

Publication number
DE60016209D1
DE60016209D1 DE60016209T DE60016209T DE60016209D1 DE 60016209 D1 DE60016209 D1 DE 60016209D1 DE 60016209 T DE60016209 T DE 60016209T DE 60016209 T DE60016209 T DE 60016209T DE 60016209 D1 DE60016209 D1 DE 60016209D1
Authority
DE
Germany
Prior art keywords
interim products
hemisynthetic
hemisynthetic method
interim
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60016209T
Other languages
English (en)
Other versions
DE60016209T2 (de
Inventor
Carmen Cuevas
Marta Perez
Andres Francesch
Carolina Fernandez
Jose Luis Chicharro
Pilar Gallego
Maria Zarzuelo
La Calle Fernando De
Ignacio Manzanares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911345.8A external-priority patent/GB9911345D0/en
Priority claimed from GBGB9918178.6A external-priority patent/GB9918178D0/en
Priority claimed from GBGB9923632.5A external-priority patent/GB9923632D0/en
Priority claimed from GB0001063A external-priority patent/GB0001063D0/en
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of DE60016209D1 publication Critical patent/DE60016209D1/de
Application granted granted Critical
Publication of DE60016209T2 publication Critical patent/DE60016209T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
DE60016209T 1999-05-14 2000-05-15 Hemisynthetisches verfahren und dessen zwischenprudukte Expired - Lifetime DE60016209T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB9911345 1999-05-14
GBGB9911345.8A GB9911345D0 (de) 1999-05-14 1999-05-14
GBGB9918178.6A GB9918178D0 (en) 2000-05-15 1999-08-02 Synthetic methods
GB9918178 1999-08-02
GB9923632 1999-10-06
GBGB9923632.5A GB9923632D0 (en) 1999-10-06 1999-10-06 Hemisynthetic process towards ecteinascidin and phtalscidin compounds
GB0001063A GB0001063D0 (en) 2000-01-17 2000-01-17 Hemisynthetic process towards ecteinascidin and phtalascidin
GB0001063 2000-01-17
PCT/GB2000/001852 WO2000069862A2 (en) 1999-05-14 2000-05-15 Hemisynthetic method and intermediates thereof

Publications (2)

Publication Number Publication Date
DE60016209D1 true DE60016209D1 (de) 2004-12-30
DE60016209T2 DE60016209T2 (de) 2005-12-15

Family

ID=42632476

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60016209T Expired - Lifetime DE60016209T2 (de) 1999-05-14 2000-05-15 Hemisynthetisches verfahren und dessen zwischenprudukte

Country Status (29)

Country Link
US (3) US7241892B1 (de)
EP (1) EP1185536B1 (de)
JP (1) JP4445136B2 (de)
KR (1) KR100834601B1 (de)
CN (3) CN1229382C (de)
AR (1) AR035842A1 (de)
AT (1) ATE283273T1 (de)
AU (2) AU775580B2 (de)
BG (1) BG65896B1 (de)
BR (3) BRPI0010559B8 (de)
CA (2) CA2372058C (de)
CY (1) CY1108095T1 (de)
CZ (3) CZ303536B6 (de)
DE (1) DE60016209T2 (de)
DK (1) DK1185536T3 (de)
ES (2) ES2233367T3 (de)
HU (1) HU230646B1 (de)
MX (1) MXPA01011631A (de)
MY (1) MY130271A (de)
NO (2) NO322016B1 (de)
NZ (1) NZ515424A (de)
PL (1) PL226890B1 (de)
PT (1) PT1185536E (de)
RU (1) RU2237063C9 (de)
SI (2) SI1185536T1 (de)
SK (2) SK287835B6 (de)
TR (1) TR200103273T2 (de)
UA (1) UA75333C2 (de)
WO (3) WO2000069862A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003470T2 (tr) 1998-05-11 2001-06-21 Pharama Mar, S.A. Ecteinascidin 743 Metabolitleri
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
JP5219323B2 (ja) 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
JP4942900B2 (ja) * 2000-05-15 2012-05-30 ファルマ・マール・ソシエダード・アノニマ エクチナサイジン化合物の製造のための合成方法
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
AU3956502A (en) 2000-11-03 2002-05-27 Harvard College Saframycins, analogues and uses thereof
JP4391083B2 (ja) * 2000-11-06 2009-12-24 ファルマ・マール・ソシエダード・アノニマ 効果的な抗腫瘍治療
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
KR20050038578A (ko) * 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7183054B2 (en) 2003-06-03 2007-02-27 President And Fellows Of Harvard College Assay for identifying biological targets of polynucleotide-binding compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DK1689404T3 (da) 2003-11-13 2009-01-26 Pharma Mar Sau Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
CN101068596A (zh) * 2004-09-29 2007-11-07 法马马私人股份有限公司 艾可特耐思地作抗炎药
ATE430586T1 (de) * 2004-10-26 2009-05-15 Pharma Mar Sa Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
KR100712667B1 (ko) 2006-04-11 2007-05-02 재단법인서울대학교산학협력재단 신규한 디아자 헤테로고리 유도체 및 그의 고체상 제조방법
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a
US20090076017A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched trabectedin
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
WO2009138509A1 (en) * 2008-05-16 2009-11-19 Pharma Mar, S.A. Multiple myeloma treatments
KR20110025178A (ko) * 2008-05-16 2011-03-09 파르마 마르 에스.에이. Pm00104 및 다른 항종양제를 이용한 복합 치료법
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
EP2576569B1 (de) 2010-05-25 2015-01-14 Pharma Mar S.A. Synthetisches verfahren zur herstellung von ecteinascidinverbindungen und zwischenverbindungen
PT2786756T (pt) 2010-11-12 2020-05-07 Pharma Mar Sa Terapia de combinação com um inibidor de topoisomerase
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN107739387B (zh) * 2017-10-16 2020-01-03 上海皓元生物医药科技有限公司 一种制备曲贝替定的关键中间体化合物的方法
CN109912629B (zh) * 2017-12-13 2021-12-24 浙江中科创越药业有限公司 天然产物Trabectedin的制备
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN111518110B (zh) * 2019-02-01 2023-11-03 博瑞生物医药(苏州)股份有限公司 一种海鞘素化合物及其中间体的制备方法
CN111620792B (zh) * 2019-02-28 2023-01-03 兰州大学 一种n,n-二取代氰基甲酰胺的合成方法
CN118924689A (zh) 2019-11-21 2024-11-12 法马马有限公司 用鲁比卡丁制剂治疗小细胞肺癌的方法
CN116217584A (zh) * 2021-12-06 2023-06-06 南通诺泰生物医药技术有限公司 Et743及其中间体的光催化合成方法
AU2024210894A1 (en) * 2023-01-17 2025-07-17 Adcytherix Sas Ecteinascidin derivative antibody drug conjugates
WO2025077996A1 (en) 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
WO2025233522A1 (en) 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin
WO2026022359A2 (en) 2024-07-26 2026-01-29 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2461995A1 (fr) * 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6054386A (ja) * 1983-09-02 1985-03-28 Yoshitomi Pharmaceut Ind Ltd サフラシン誘導体
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
JP2562162B2 (ja) 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン729、743、745、759a、759bおよび770
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
ATE370148T1 (de) * 1998-04-06 2007-09-15 Univ Illinois Halbsynthetische ectein-ascidine
TR200003470T2 (tr) 1998-05-11 2001-06-21 Pharama Mar, S.A. Ecteinascidin 743 Metabolitleri
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US6686470B2 (en) 2000-01-19 2004-02-03 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
JP5219323B2 (ja) 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Also Published As

Publication number Publication date
BRPI0110801B8 (pt) 2021-05-25
WO2001087894A1 (en) 2001-11-22
NO20015547L (no) 2002-01-14
PL353002A1 (en) 2003-09-22
BRPI0110801B1 (pt) 2018-02-27
JP2002544280A (ja) 2002-12-24
PL226890B1 (pl) 2017-09-29
SK287835B6 (sk) 2011-12-05
CZ20023751A3 (en) 2004-05-12
US20040002602A1 (en) 2004-01-01
KR100834601B1 (ko) 2008-06-02
BR0010559A (pt) 2002-07-02
CZ20023746A3 (cs) 2003-04-16
DK1185536T3 (da) 2005-04-04
BG65896B1 (bg) 2010-04-30
CN1229382C (zh) 2005-11-30
CY1108095T1 (el) 2014-02-12
CN1441805A (zh) 2003-09-10
WO2000069862A2 (en) 2000-11-23
BR0110443A (pt) 2003-04-08
US20080045713A1 (en) 2008-02-21
NO20025186L (no) 2003-01-14
CZ303536B6 (cs) 2012-11-21
KR20020021636A (ko) 2002-03-21
CZ304973B6 (cs) 2015-02-25
HU230646B1 (hu) 2017-05-29
CA2406095A1 (en) 2001-11-22
ES2231486T3 (es) 2005-05-16
AU775580B2 (en) 2004-08-05
US7524956B2 (en) 2009-04-28
NO322016B1 (no) 2006-08-07
BR0110801A (pt) 2003-02-11
WO2001087895A1 (en) 2001-11-22
SK287879B6 (sk) 2012-02-03
BRPI0010559B8 (pt) 2021-05-25
RU2237063C2 (ru) 2004-09-27
TR200103273T2 (tr) 2002-04-22
JP4445136B2 (ja) 2010-04-07
HK1047432A1 (en) 2003-02-21
ES2233367T3 (es) 2005-06-16
NO20025186D0 (no) 2002-10-29
RU2237063C9 (ru) 2008-10-10
CA2372058C (en) 2010-10-26
AU4597300A (en) 2000-12-05
HUP0201188A2 (en) 2002-07-29
NO328301B1 (no) 2010-01-25
UA75333C2 (uk) 2006-04-17
EP1185536B1 (de) 2004-11-24
CN1440414A (zh) 2003-09-03
AR035842A1 (es) 2004-07-21
CN1211386C (zh) 2005-07-20
BRPI0110443B8 (pt) 2021-05-25
EP1185536A2 (de) 2002-03-13
BRPI0110443B1 (pt) 2018-06-26
MXPA01011631A (es) 2002-07-30
SI1185536T1 (en) 2005-06-30
WO2000069862A3 (en) 2001-03-22
NO20015547D0 (no) 2001-11-13
SK16502001A3 (sk) 2002-06-04
CA2406095C (en) 2010-02-16
CZ304966B6 (cs) 2015-02-18
BG107301A (bg) 2003-07-31
NZ515424A (en) 2004-06-25
SK15272002A3 (sk) 2003-06-03
PT1185536E (pt) 2005-04-29
CA2372058A1 (en) 2000-11-23
CN1360588A (zh) 2002-07-24
CZ20014102A3 (cs) 2002-06-12
US7241892B1 (en) 2007-07-10
AU5649601A (en) 2001-11-26
BRPI0010559B1 (pt) 2016-08-30
SI1287004T1 (sl) 2005-12-31
MY130271A (en) 2007-06-29
CN100475822C (zh) 2009-04-08
DE60016209T2 (de) 2005-12-15
ATE283273T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
DE60016209D1 (de) Hemisynthetisches verfahren und dessen zwischenprudukte
DE69834401D1 (de) Businterfacesystem und verfahren
DE60027698D1 (de) Lasttragendes osteoimplantat und verfahren zu seiner herstellung
DE60026034D1 (de) Zusammendrückbeständiges mikriporöses material und verfahren zu seiner herstellung
ATE379971T1 (de) Disinfektionsmittel und verfahren zu dessen herstellung
DE69838230D1 (de) Frequenzumsetzer und verfahren
FI19992360L (fi) Tuote ja menetelmä sen valmistamiseksi
ATE311741T1 (de) Ernteverfahren und erntevorrichtung
DE59810418D1 (de) Aufgeweiteter stent und verfahren zum herstellen desselben
DE60039438D1 (de) Elektrostatischer ultraschallwandler und verfahren zu dessen herstellung
DE60013027D1 (de) Bauteil und Verfahren zu seiner Herstellung
DE69913180D1 (de) Extraktionseinheiten und verfahren
DE69823540D1 (de) Sterilisationsverpackung und verfahren
DE69942382D1 (de) Sensor und verfahren zu dessen herstellung
DE60017552D1 (de) Geschaeumte schokolade und verfahren zu dessen herstellung
DE60018049D1 (de) Ionisationsstab und verfahren zu dessen herstellung
ATE555078T1 (de) Verfahren und zwischenprodukte
DE60019627D1 (de) Ferrofluid-zusammensetzung und verfahren
ATE286658T1 (de) Teigformmaschine und verfahren
DE59914950D1 (de) Feldeffektgesteuerter transistor und verfahren zu dessen herstellung
EP1054607A4 (de) Mikrohaftverschluss und verfahren zu dessen herstellung
DE69905326D1 (de) Sollerschlitz und Verfahren zu dessen Herstellung
DE69939280D1 (de) Sende-Empfänger und Verfahren
DE59912840D1 (de) Elektromagnetischer durchflussmesser und verfahren zu seiner herstellung
ATA75297A (de) Dekorlaminat und verfahren zu seiner herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition